After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...

Kennedy, a long-time opponent of vaccines, stated that the MMR vaccine is “the most effective way” to combat the measles ...

Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...